CLYM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

5 Analyst Rating

Wall Street analysts forecast CLYM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLYM is 9.25 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

9.25

High

10.00

Current: 0.000

Low

8.00

Averages

9.25

High

10.00

William Blair

Matt Phipps

Outperform

initiated

2025-10-16

Reason

William Blair

Matt Phipps

Price Target

2025-10-16

initiated

Outperform

Reason

William Blair analyst Matt Phipps initiated coverage of Climb Bio with an Outperform rating and no price target. The firm cites the potential of the company's CD19 antibody, budoprutug, which is being developed across a range of autoimmune indications, for the rating. The simplicity of a monoclonal antibody will be attractive for community physicians who treat most autoimmune patients, the analyst tells investors in a research note.

BTIG

Buy

maintain

$7 -> $8

2025-09-30

Reason

BTIG

Price Target

$7 -> $8

2025-09-30

maintain

Buy

Reason

BTIG raised the firm's price target on Climb Bio to $8 from $7 and keeps a Buy rating on the shares. With a positive dose-response seen with sibeprenlimab in IgAN, the firm believes that CLYM116 is well-positioned to drive even greater efficacy at two to three-times the half life compared to sibeprenlimab in NHPs - nonhuman primate, the analyst tells investors in a research note. The long half life also refuted any speculation that target-mediated drug disposition could impair CLYM116's PK, the firm added.

Baird

Outperform

initiated

2025-08-15

Reason

Baird

Price Target

2025-08-15

initiated

Outperform

Reason

As previously reported, Baird initiated coverage of Climb Bio with an Outperform rating and $9 price target. The firm believes Climb's lead drug budoprutug has potential across a wide range of immune-mediated diseases, building on validation from Uplizna, the analyst tells investors. Early clinical data for budoprutug in primary membranous nephropathy have shown positive efficacy and safety, notes the analyst, who adds that Climb is currently pursuing early-to-mid-stage studies in pMN as well as immune thrombocytopenia and systemic lupus erythematosus.

Baird

Colleen Kusy

Outperform

initiated

2025-08-14

Reason

Baird

Colleen Kusy

Price Target

2025-08-14

initiated

Outperform

Reason

Baird analyst Colleen Kusy initiated coverage of Climb Bio with an Outperform rating and $9 price target.

Oppenheimer

Outperform

initiated

$10

2025-06-06

Reason

Oppenheimer

Price Target

$10

2025-06-06

initiated

Outperform

Reason

Oppenheimer initiated coverage of Climb Bio with an Outperform rating and $10 price target. The company's lead candidate IV budoprutug drives Oppenheimer's enthusiasm as this "prospective best-in-class" anti-CD19 antibody advances for several poorly-met autoimmune conditions, the analyst tells investors in a research note. The firm says an encouraging efficacy signal in patients with primary membranous nephropathy makes it optimistic for a soon-to-begin Phase 2, and initial trials in immune thrombocytopenia and lupus should begin imminently. Opco sees $1B-plus sales potential across these indications.

BTIG

analyst

initiated

2025-05-22

Reason

BTIG

analyst

Price Target

2025-05-22

initiated

Reason

BTIG initiated coverage of Climb Bio with a Buy rating and $7 price target. Climb's budoprutug is only the second anti-CD19 monoclonal antibody that has been advanced into the clinic for immunology and inflammation development, says the analyst, who views "Uplizna 2.0" as well-positioned to thrive in a wide range of I&I opportunities. The firm expects budoprutug to emerge as the best-in-class mAb supported by a longer half-life, higher solubility, and higher affinity compared to Uplizna, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Climb Bio Inc (CLYM.O) is -4.62, compared to its 5-year average forward P/E of -3.41. For a more detailed relative valuation and DCF analysis to assess Climb Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.41

Current PE

-4.62

Overvalued PE

-1.59

Undervalued PE

-5.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

-0.06

Overvalued EV/EBITDA

0.12

Undervalued EV/EBITDA

-0.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CLYM News & Events

Events Timeline

No data

News

6.0

2025-12-18Benzinga

GE Vernova Expected to Surge by 33%? Check Out 10 Leading Analyst Predictions for Thursday

9.0

2025-12-15NASDAQ.COM

Promising Data on the Horizon: Can 2026 Results Propel Climb Bio Forward?

5.0

2025-10-21Newsfilter

Climb Bio Appoints Adam Villa as Senior Vice President of Technical Operations and Ashley Jones as Senior Vice President of People and Workforce Strategy

People Also Watch

Frequently Asked Questions

What is Climb Bio Inc (CLYM) stock price today?

The current price of CLYM is 5.03 USD — it has increased 9.83 % in the last trading day.

What is Climb Bio Inc (CLYM)'s business?

Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

What is the price predicton of CLYM Stock?

What is Climb Bio Inc (CLYM)'s revenue for the last quarter?

Climb Bio Inc revenue for the last quarter amounts to -14.89M USD, increased 26.93 % YoY.

What is Climb Bio Inc (CLYM)'s earnings per share (EPS) for the last quarter?

Climb Bio Inc. EPS for the last quarter amounts to -12248000.00 USD, increased 62.12 % YoY.

What changes have occurred in the market's expectations for Climb Bio Inc (CLYM)'s fundamentals?

The market is revising No Change the revenue expectations for Climb Bio, Inc. (CLYM) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 166.14%.

How many employees does Climb Bio Inc (CLYM). have?

Climb Bio Inc (CLYM) has 17 emplpoyees as of January 10 2026.

What is Climb Bio Inc (CLYM) market cap?

Today CLYM has the market capitalization of 342.97M USD.